Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind study of teplizumab in newly diagnosed Stage 3 type 1 diabetes
jRCT2051250224Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Teplizumab with Placebo (2 arms). Primary endpoints: HbA1c change from baseline (US and non-EU countries), Total number of days without prandial insulin use (US and non-EU countries) and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2051250224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250224.